Core Viewpoint - The market is experiencing a phase of adjustment after a period of overheating, primarily due to expectations of tightening overseas liquidity and pressure from cyclical sector corrections [1][5]. Group 1: Market Outlook - February is identified as a rare performance vacuum period, with a stable situation in the Asia-Pacific region; however, the extended Spring Festival may lead to early profit-taking by some funds [6]. - The market is expected to exhibit a volatile pattern, emphasizing the importance of stock selection [6]. Group 2: Investment Opportunities in Medical Technology - The company remains optimistic about the ongoing wave of technological innovation in the medical and consumer sectors, particularly driven by AI and domestic industry advancements, which present investment opportunities in the Chinese capital market [7][8]. - Key areas of focus include AI in healthcare, brain-computer interfaces, surgical robots, AI-driven innovative drugs, innovative medical devices, and cell gene nucleic acid therapies [7][8]. Group 3: New Logic for Innovative Drugs - The previous BD (business development) trading model for innovative drugs is losing effectiveness, necessitating a new guiding logic for the capital market to foster a new market trend [9]. - Three potential directions for innovative drugs are identified: 1. Core value return, where the globalization of domestic innovative drugs does not require excessive speculation 2. Performance explosion, with some outbound platform-type innovative drug companies expected to show nonlinear profit releases 3. Positive cycle of BD trading, where market sentiment is cyclical, transitioning from excessive enthusiasm to extreme lows, leading to a significant drop in overseas BD expectations for many companies [9].

Market Overview - The spring market has experienced a pause with significant corrections in gold and silver prices, leading to a wide fluctuation in global markets. However, the market quickly stabilized after the initial downturn, with COMEX gold recovering to 5000 points and the Shanghai Composite Index stabilizing around 4100 points [1][13]. - Affected by overseas uncertainties, A-shares saw a substantial adjustment but rebounded on February 3, demonstrating strong market resilience [2][13]. Long-term Opportunities - The new productive forces are becoming the engine for economic growth, with an increasing share of "new economy" stocks in the market. AI is expected to see application results this year, alongside sectors like innovative pharmaceuticals and energy storage entering a favorable cycle [3][14]. - A-shares are attractive in terms of valuation compared to major global markets, with low foreign capital positions and the establishment of mechanisms for long-term domestic funds entering the market. The trend of "deposit migration" among residents may continue in a low-interest-rate environment [3][14][15]. - Policy emphasis on expanding domestic demand and stimulating consumption is expected to translate into systematic improvements in corporate profitability. Following the Spring Festival, policy catalysts are anticipated to accelerate, potentially leading to better index performance post-holiday [15]. Sector Focus - The market is expected to focus on cyclical price increases, with sectors like oil and petrochemicals, food and beverage, AI, and semiconductors continuing to see positive trends. The construction materials sector may benefit from major projects under the 14th Five-Year Plan [15]. - Investors are encouraged to consider broad-based products like the CSI A500 ETF (159338) for exposure to industry leaders, as well as a tech + dividend "barbell" strategy as a satellite approach [4][15]. Commodity Market Insights - The gold market has faced its largest drawdown in 40 years but has quickly rebounded, indicating that the bull market is likely not over yet. Historical context suggests that significant narrative shifts are required to signal the end of a bull market [5][16]. - From a macro perspective, a super cycle in commodities is anticipated this year, with fundamental factors driving long-term trends. The black and chemical sectors, currently at relatively low levels, may offer better value post-adjustment [8][17]. Investment Strategies - For investors concerned about market volatility, "fixed income plus" products are recommended. These strategies focus on safety and stability while allowing for some equity exposure to capture market gains [19][20]. - An example is the Guotai Helix 6-month holding mixed fund, which combines high-grade credit bonds for the fixed income portion and a flexible allocation to equities, aiming for a balanced approach to risk and return [20][21].

Core Viewpoint - The Hong Kong stock technology sector is experiencing a pullback, with the Hong Kong Technology ETF (513020) declining over 0.8%, but it has seen net inflows for three consecutive days, indicating potential for positioning during the pullback [1] Group 1: Industry Trends - The dual main lines of industry fundamentals for the next 3-5 years are technology and overseas expansion, which are reshaping the market's profit structure and are expected to drive profits into a new upward cycle by 2026-2027 [1] - The essence of the "new" is the transition of AI technology to downstream applications, moving from infrastructure to supply-demand gaps, with upstream focus on copper, storage, and power equipment, and downstream focus on AI applications and components [1] - The "old" essence involves traditional industries moving away from outdated models, with profits from overseas business stabilizing and growing, extending the trend from downstream manufacturing to midstream and upstream sectors such as engineering machinery, wind power, electrical equipment, chemicals, building materials, and industrial metals [1] Group 2: Index Performance - The Hong Kong Technology ETF (513020) tracks the Hong Kong Stock Connect Technology Index (931573), which covers core assets in Hong Kong's technology sector, including internet, semiconductors, innovative pharmaceuticals, and new energy vehicles, reflecting the diversified characteristics of the technology industry [1] - From the base date at the end of 2014 to the end of 2025, the Hong Kong Stock Connect Technology Index has achieved a cumulative return of 224.25%, outperforming the Hang Seng Technology Index (83.87%) by over 140%, consistently beating similar indices [2]

东海证券指出，2025年创新药板块进入盈利兑现提速期，龙头逐步实现扭亏为盈，核心驱动主要来自商 业化产品快速放量和BD合作两大主线。创新药板块靓丽的业绩表现，充分验证了国产创新药商业模式 的有效性，医保加持下的核心产品放量成为业绩增长基础，BD等对外合作则成为业绩增厚的重要抓 手。这也推动板块投资逻辑进一步向"真盈利、硬创新"聚焦。 每日经济新闻 风险提示：提及个股仅用于行业事件分析，不构成任何个股推荐或投资建议。指数等短期涨跌仅供参 考，不代表其未来表现，亦不构成对基金业绩的承诺或保证。观点可能随市场环境变化而调整，不构成 投资建议或承诺。提及基金风险收益特征各不相同，敬请投资者仔细阅读基金法律文件，充分了解产品 要素、风险等级及收益分配原则，选择与自身风险承受能力匹配的产品，谨慎投资。 创业板医药ETF国泰（159377）跟踪的是创医药指数（399275），单日涨跌幅限制达20%，该指数从创 业板市场中选取涉及生物制药、医疗器械、医疗服务等医药健康领域的上市公司证券作为指数样本，以 反映创业板医药行业相关上市公司证券的整体表现。 ...

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index (HSSCPB) decreased by 1.40% as of February 5, 2026, with mixed performance among constituent stocks [1] - Notable gainers included Nocera Healthcare up 3.87%, Four Seasons Pharmaceutical up 3.14%, and Heng Rui Medicine up 2.77%, while MIRXES-B led the decline down 9.12% [1] - The Hong Kong Innovative Drug ETF (520690) fell by 1.20%, with a latest price of 0.82 yuan, but showed a 2.97% increase over the past month as of February 4, 2026 [1] Group 2 - As of January 31, 2026, 283 pharmaceutical stocks disclosed their 2025 earnings forecasts, with 160 stocks expected to see year-on-year profit growth, highlighting a positive trend in the innovative drug sector [2] - Sino Medical emerged as the "profit growth king" in A-shares with a forecasted increase of over 32 times, while WuXi AppTec is expected to achieve a record net profit of 19.151 billion yuan [2] - The demand for weight loss drugs remains strong, with Eli Lilly reporting a 43% year-on-year revenue increase to $19.29 billion in Q4, exceeding market expectations [2] Group 3 - Donghai Securities indicated that the innovative drug sector is entering a phase of accelerated profit realization, driven by rapid commercialization of products and business development collaborations [3] - The performance of the innovative drug sector validates the effectiveness of the domestic innovative drug business model, with core products supported by medical insurance driving growth [3] - The Hong Kong Innovative Drug ETF has seen continuous net inflows, totaling 16.3621 million yuan over three days, with a maximum single-day inflow of 8.9766 million yuan [3]

信达生物2月4日公布其2025全年业绩，总产品收入约人民币119亿元，同比保持约45%的强劲增长态 势。2025年Q4，信达生物有6款新药纳入2026年国家医保目录。 东海证券表示，2025年创新药板块进入盈利兑现提速期，诺诚健华、荣昌生物等实现扭亏为盈，三生国 健等业绩大幅预增，君实生物等显著减亏，核心驱动主要来自商业化产品快速放量和BD合作两大主 线。 2月5日早盘，港股市场主要指数集体下挫，聚焦创新药、AI医疗主线的港股通医疗ETF(520510)一度逆 势翻红，脑动极光、药明康德（603259）、凯莱英（002821）等持仓股涨幅靠前。 ...

美国：沃什提名后引发了反向交易 国信证券主要观点如下： 当市场预期全年降息的逻辑过于一致时，沃什的提名引发了缩表的预期并带来了美元指数的反弹。当下 为此担忧还尚早，由于美国上半年的时薪、消费、就业压力均较大，且上半年通胀的压力不大，故而降 息的必要性依然较高；另外，关于缩表的更多信息要到5月份主席换届之后才将逐渐清晰。 智通财经APP获悉，国信证券发布研报称，1月美股上涨幅度显著小于新兴市场，将美元指数反弹看成 是阶段性，26年上半年依然认为新兴市场机会更大。但有两个风险需要跟踪：一是原油价格因地缘冲突 的大幅上涨；二是长债利率继续向上大幅攀升。美元指数反弹，美债利率上行一定程度上对港股的资金 面产生负面影响。但人民币升值依旧，港股业绩稳健上修，以及并不认为美元指数反弹能够持续，故而 依然看好港股后续的行情。板块方面，建议关注AI、PPI方向原材料及工业等。 1、AI方向：AI方向产生分化，景气部分是半导体、云计算、算力链，而应用方向短期受到外卖战、去 年筹码较为拥挤的影响表现不佳，随着外卖战的减弱以及价格的回调，加之大模型应用场景的不断丰 富，AI应用依然是2026年的战略方向之一。 2、PPI方向的原材料 ...

Group 1 - The core viewpoint is that the A-shares and Hong Kong stocks are expected to continue a slow bull market trend in the upcoming Year of the Horse, with a noticeable increase in market profitability and further sector rotation anticipated [1] - Different sectors are being referred to in a way that reflects structural differentiation: technology stocks are humorously called "small Deng stocks," while traditional sectors like liquor are referred to as "old Deng stocks." New energy, military industry, and non-ferrous metals (including precious metals) are seen as "medium Deng stocks" [1] - The expected order of sector rotation in a slow bull market is "first small Deng, then medium Deng, and finally old Deng" [1] Group 2 - In terms of industry allocation, it is essential to align with the "14th Five-Year Plan" and relevant policy directions, with a focus on technological innovation [1] - Key areas of focus in the technology sector include semiconductor chips, artificial intelligence, innovative pharmaceuticals, solid-state batteries, and computing power algorithms, as well as future technologies like controllable nuclear fusion and quantum technology [1] - The real estate sector is still in an adjustment period, but core areas in first-tier cities may see a rebound due to scarcity and demand support, with transaction volumes potentially increasing [1] Group 3 - In the precious metals sector, the price increase in the Year of the Horse is unlikely to replicate the gains of the past two years due to already high price levels, but the long-term trend remains unchanged [2] - Allocating about 20% of an investment portfolio to gold assets over a 5-10 year horizon is still considered an effective way to hedge against inflation and currency devaluation [2]

Group 1 - The innovative drug sector experienced a significant upward trend on February 4, with notable gains in several companies [2] - HaiTe Bio saw an increase of over 8%, while GuangShengTang rose by more than 6% [2] - Other companies such as KangChen Pharmaceutical, ShuTaiShen, XinLiTai, BeiLu Pharmaceutical, and Tigermed also showed positive movement in their stock prices [2]

Core Insights - The article emphasizes the importance of capturing investment opportunities aligned with China's 14th Five-Year Plan, focusing on high-quality development and technological self-reliance [1][2] Investment Strategies - The investment landscape for 2026 is shaped by the "14th Five-Year Plan," which serves as a guiding framework for strategic investments, emphasizing high-quality development and innovation [2] - Key investment opportunities are identified in three main sectors: traditional industries (e.g., chemicals, shipbuilding), emerging industries (e.g., AI, energy storage), and frontier technologies (e.g., embodied intelligence, nuclear fusion) [2] Innovation in Pharmaceuticals - Chinese innovative pharmaceutical companies are expected to experience significant growth, with the total amount of License-out agreements projected to exceed $121.6 billion by 2025, doubling from 2024 [3] - The introduction of AI models is anticipated to shorten drug development cycles and enhance success rates, leading to a revaluation of the innovative drug sector [3] Hong Kong Market Outlook - The Hong Kong stock market is viewed positively, with major investment banks highlighting the resilience and vitality of the Chinese economy, making it a preferred choice for asset allocation [4][5] - The analysis of Hong Kong tech assets reveals two main investment themes: a return to EPS growth and cash flow recovery, alongside a focus on leading internet platforms and emerging industries like smart driving [5] AI Industry Insights - AI is positioned as a transformative force comparable to previous industrial revolutions, with significant growth potential as applications become more widespread [6] - The commercialization of AI applications, particularly in smart driving and robotics, is expected to gain momentum, presenting investment opportunities in related companies [6] Renewable Energy Sector - The renewable energy sector is forecasted to continue its upward trend, with significant opportunities in lithium battery technology and new materials, particularly solid-state batteries [7] - The chemical industry is also expected to see a recovery in profitability, driven by demand growth and supply-side reforms [7] Financial and Real Estate Sector - The financial and real estate sectors are showing signs of recovery, with a rebound in second-hand housing transactions and improved profitability for insurance companies [8] - Investment opportunities are emerging in quality real estate firms and banks with strong wealth management capabilities [8] Consumer Sector Trends - The consumer sector is experiencing a shift, with new growth areas such as smart home products and outdoor lifestyle gaining traction [11] - The changing demographics and consumer preferences are expected to drive growth in sectors like travel, healthcare, and wellness [11] Fixed Income Investment Strategies - The fixed income market is anticipated to remain stable, with a focus on short-term and medium-term bond funds for liquidity and steady growth [14] - The overall bond market is expected to exhibit a fluctuating pattern, influenced by monetary policy and economic data [14]